Targeted anti-vascular therapies for ovarian cancer: current evidence
about
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectivesRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerNew perspectives on targeted therapy in ovarian cancerCombinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatinGenome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogueClodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancerInterleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.Role of the angiopoietin/Tie system in pregnancy (Review).The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway.GyneScan: an improved online paradigm for screening of ovarian cancer via tissue characterization.The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression.The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis.Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review)Ovarian cancer: genomic analysis.Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume.Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity.Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.Targeting tyrosine-kinases in ovarian cancer.Sphingosine 1-phosphate: a potential molecular target for ovarian cancer therapy?Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.Bevacizumab treatment and quality of life in advanced ovarian cancer.Ex vivo Determination of an Estradiol Analogue-Induced Changes on Platelet Morphology and Angiogenic Biomarkers.Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia.Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer.Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients.Isoprenaline/β2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis.Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
P2860
Q26749280-B6E56CB9-634A-4EDA-83E0-B5787233C65EQ26780387-B2DAAB11-EE16-4B3F-A404-1FB89DD7E2ECQ28082524-1CDB5819-9181-484C-9309-1AD2E44062D9Q28537820-85B516B8-4198-4094-BACD-EFD603002F02Q28541775-423DF727-4EA6-4EFC-A245-32A15ABB2C40Q33989948-2FC49772-F825-42EF-A80D-0C157DAD9C93Q35014881-BC5B7E63-ACAC-4A77-A8CA-1654435809E0Q35035679-08D2679F-ACDF-47E2-A95B-DD88BF9D62A0Q35058009-8A86D275-9555-44C5-99A2-98DF342409BEQ35159581-F358FBCF-4293-40F5-813B-A0CB3DF7A663Q35539229-09FA3B8C-195A-4170-BB75-E479C4313255Q35852757-00B9D01A-9351-49B9-B6E9-92F4CDC00130Q35853946-A5330A1E-87E0-4F4A-9A83-86BD19AC4D61Q35924031-944FEEC9-FECF-409D-B571-E6E09593DA5DQ35986338-0EF6975B-82C4-41FC-B7BE-B6D576B032B6Q36183027-37126C4B-7D13-41EA-875E-C0B604C3AF5AQ36761574-187526F3-C671-4D47-B982-7B5F4B54B4E1Q37265655-251FA6F1-A099-4AEF-B46A-75B0AC760631Q37332480-B74EFBD1-949A-4988-8EFF-D0C1184210DAQ37495153-DAFD638C-299A-44A5-A9A6-B33F8053BDBCQ37651981-20B0A1EA-C995-45C1-BB18-2B507AF367DDQ38111265-38CFAC5C-FE0F-40CD-BB01-83074BC0CCDBQ38118388-36F87337-7E53-4076-B7D8-C2FC0FF0BFFCQ38185438-2570AB6D-2744-4E23-AAD6-EC75FCC4D2ABQ38340008-949AC582-DCDE-4212-92D4-66AF658B43FFQ38713930-AEDCF28B-813D-4477-9361-3CD908105C62Q39388197-B691CC88-D6B2-4FCC-BD00-2172DC799EF8Q40508336-EADDC16A-49B5-45FC-86FA-361AD4D42C63Q40521599-0E2017D3-DA01-4B10-B51B-4B0334F96507Q43235803-C513AFC5-7199-4816-B07F-808FB6F3A305Q44741721-89EFE05F-07EE-4249-8508-71783DE6A64AQ47146356-0A4F1394-ADB3-4180-9C2E-E0DB747E97A3Q47158664-D93ABA33-CA2B-45E5-B9E1-AF7EE810AC5AQ50101328-1DCE9B56-DDF8-4E05-8FF2-93E1B85595B8Q53123324-97CE4DB5-2C6B-4B70-A78C-CF11BC972A2EQ53421812-F374CDA3-3B76-487E-B685-9B4B1A0C3429Q55217694-EBDBFBB7-E604-4F86-8058-6207DBEED7B7
P2860
Targeted anti-vascular therapies for ovarian cancer: current evidence
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeted anti-vascular therapies for ovarian cancer: current evidence
@ast
Targeted anti-vascular therapies for ovarian cancer: current evidence
@en
Targeted anti-vascular therapies for ovarian cancer: current evidence
@nl
type
label
Targeted anti-vascular therapies for ovarian cancer: current evidence
@ast
Targeted anti-vascular therapies for ovarian cancer: current evidence
@en
Targeted anti-vascular therapies for ovarian cancer: current evidence
@nl
prefLabel
Targeted anti-vascular therapies for ovarian cancer: current evidence
@ast
Targeted anti-vascular therapies for ovarian cancer: current evidence
@en
Targeted anti-vascular therapies for ovarian cancer: current evidence
@nl
P2093
P2860
P50
P3181
P356
P1476
Targeted anti-vascular therapies for ovarian cancer: current evidence
@en
P2093
P2860
P2888
P3181
P356
10.1038/BJC.2012.541
P407
P5008
P5530
P577
2013-02-05T00:00:00Z
P5875
P6179
1041239039